June 20, 2012
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNM SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNM prior to publication. Questions and comments may be directed to SmartBrief at

SNM SmartBrief Special Report:
A recap of the SNM Annual Meeting
Featuring new research on therapies and tools for clinical evaluation as well as discussions of health care reform and comparative effectiveness research and a vote to change the society's name to the Society of Nuclear Medicine and Molecular Imaging, this year's conference was groundbreaking. This report highlights some of the major developments from the meeting and features a look ahead from the society's new president.
  Clinical Research 
  • Study: Skin patch effective against basal cell carcinoma
    Facial tumors were eliminated in eight in 10 patients treated for basal cell carcinoma using a skin patch that delivers the phosphorus-32 radioisotope directly to the lesion, according to research presented at the SNM Annual Meeting. Patients were treated on an outpatient basis three times, and they were evaluated three months and again three years after treatment. The patch could serve as an easy, affordable therapy for patients with skin cancer, but researchers said further study in a larger group of patients is needed. (free registration) (6/12) LinkedInFacebookTwitterEmail this Story
  • Radium-223 chloride shows promise for prostate cancer
    Radium-223 chloride radioisotope therapy delayed the onset of complications and improved survival without causing serious side effects in patients with late-stage prostate cancer, according to preliminary findings presented at the SNM Annual Meeting. Average survival in patients who received the treatment was extended 3.6 months over those who did not get the treatment. Radium-223 chloride works by targeting metastases while sparing adjacent tissues. (6/14) LinkedInFacebookTwitterEmail this Story
  • PET/CT with Ga-68 alters neuroendocrine cancer treatment
    PET/CT with Gallium-68 plus a compound that behaves similarly to key regulatory hormones highlights "hot spots" that allow for better assessment of treatment options for neuroendocrine cancer, according to results presented at the SNM Annual Meeting. Treatment plans were altered in 36% of cases, including eight of 29 patients whose tumors had previously been deemed inoperable. The study was based at the University of Zurich in Switzerland. Diagnostic Imaging (6/12) LinkedInFacebookTwitterEmail this Story
  • Other News
Join Astellas for an engaging free webinar
This live, online presentation will provide an overview of the Appropriate Use Criteria (AUC) for Radionuclide Imaging, offer guidance on the implementation process, review accreditation requirements and resources, and present case studies in which the AUC have been utilized. Click here to register.

  Imaging in Practice 
  • Researchers cut redundancy in PET/CT to reduce radiation
    South Korean researchers have developed a protocol to reduce the PET/CT radiation dose in the diagnosis of Alzheimer's disease. The technique involves using only one CT scan and aligning the data with results from multiple PET scans, according to a study presented at the SNM Annual Meeting in Miami Beach, Fla. The study used a novel radiotracer known as F-18 SNUBH-NM-333. (free registration) (6/12) LinkedInFacebookTwitterEmail this Story
  • Expert: Imaging can answer dementia diagnosis challenges
    Imaging will become more important as treatments are developed for Alzheimer's disease and other forms of dementia, including dementia with Lewy bodies and frontotemporal lobe dementia, according to Dr. Kirk A. Frey, chief of nuclear medicine at the University of Michigan, who spoke at the SNM Annual Meeting. Frey discussed recent findings on the use of FDG-PET, PET with 18F-florbetapir and amyloid and dopamine terminal PET in various types of dementia. (6/13) LinkedInFacebookTwitterEmail this Story
  • Studies explore early diagnosis of Alzheimer's:
    Research discussed at the SNM Annual Meeting explored the prospect of Alzheimer's diagnoses before the onset of dementia, allowing for intervention as treatments are developed. Protocols used included PET imaging with C-11 Pittsburgh compound B, PET using F-18 florbetapir, PET with F-18 florbetaben, and a comparison of C-11 PiB PET and F-18 FDG PET. Among the findings:
    • 75% of patients with high uptake of F-18 florbetaben imaged using PET went on to develop Alzheimer's within two years.
    • C-11 Pittsburgh compound B may be useful in predicting progression to Alzheimer's.
    • Inter-reader agreement was better for PET with PiB than PET with F-18 FDG.
    • F-18 florbetapir was used to find a link between increased amyloid and reduced connectivity in certain areas of the brain, a change that was associated with poorer cognitive function.
    MedPage Today (free registration) (6/12), (6/14), Family Practice News (6/12) LinkedInFacebookTwitterEmail this Story
  • Study assesses PET/MRI in myocardial perfusion evaluation
    Use of integrated PET/MRI for myocardial perfusion scanning poses challenges, according to research presented at the SNM Annual Meeting, but it is feasible. "We found an overall good correlation between [PET and MRI]," said primary author Shelley Zhang. "Whereas resting flow agrees quite well, the stress values showed underestimation of MRI for perfusion." (free registration) (6/11) LinkedInFacebookTwitterEmail this Story
  • Other News
Join Astellas for an engaging webinar, “The Future Is Now: Implementing the AUC in Your Nuclear Lab,” led by Regina Druz, MD. Find out more here.

  The Best of SNM 
  • Image of the Year highlights radiotherapy for cancer
    The Image of the Year honor from the SNM Annual Meeting goes to German researchers whose work highlights a labeling protocol and the utility of bismuth-213 (Bi-213) DOTATOC in shrinking gastroenteropancreatic neuroendocrine tumors as well as hepatic and bone metastases. "The images illustrating the effectiveness of Bi-213 DOTATOC for GEP-NETs show the remarkable results that can be achieved in a clinical setting," said Scientific Program Committee Chairman Dr. Peter Herscovitch. (free registration) (6/11) LinkedInFacebookTwitterEmail this Story
  • Comparative effectiveness: "Huge opportunity" for imaging
    Comparative effectiveness research is challenging for imaging, Dr. Rory Hachamovitch of the Cleveland Clinic said at an SNM Annual Meeting symposium, because the direct value of imaging can't be easily assessed by traditional measures. "Imaging doesn't alter patient outcomes. It alters physician management, which alters treatment, which impacts outcomes," he said. However, Hachamovitch said imaging specialists must embrace comparative effectiveness as a way to demonstrate the value of their work in clinical decision making. (6/13) LinkedInFacebookTwitterEmail this Story
  • Society name change "a natural progression"
    More than two-thirds of SNM members attending the society's business meeting voted to change the organization's name to the Society of Nuclear Medicine and Molecular Imaging. The new name "retains our rich history and identity while recognizing the growing diversity in our field," said Dr. George M. Segall, immediate past president. Incoming president Dr. Frederic H. Fahey said, "Changing our name is part of the natural progression of the organization to embrace molecular imaging." (6/13) LinkedInFacebookTwitterEmail this Story
  • A conversation with the incoming president
    Frederic H. Fahey, DSc.
    SNM SmartBrief asked President Frederic H. Fahey to share his thoughts on society initiatives past, present and future. Dr. Fahey highlighted education and appropriate use initiatives for amyloid imaging agents, dose optimization projects, efforts to support evidence-based decision making such as through the Choosing Wisely campaign and promotion of molecular imaging. Here is some of what he had to say, in his own words:

    "It goes without saying that it is a great honor to have the opportunity to serve the SNM, the largest international organization in our field. As a nuclear medicine physicist, I want to continue with our dose optimization project. We will continue to promote the fact that when the nuclear medicine imaging study is performed correctly in the right patients, the benefits outweigh the potential risks by several orders of magnitude.

    "The further advancement of our field will require partnerships with other organizations within the U.S., including those specializing in imaging and the clinical practice of treating disease, as well as those beyond our borders with cooperation from our colleagues from around the world including Europe and Asia. However, we should also play a role in advancing nuclear medicine and molecular imaging in the developing world.

    "Lastly, the diversity of the SNM membership is one of our greatest assets. I want to hear from as many members as possible about what SNM is doing that is working, where we need to improve and how they might help." LinkedInFacebookTwitterEmail this Story

  • Did you miss the meeting?
    Catch up on everything you missed with SNM's Virtual Meeting, offering video recordings of the most popular sessions from this year's conference. LinkedInFacebookTwitterEmail this Story

Product announcements appearing in SmartBrief are paid advertisements and do not reflect actual SNM endorsements. The news reported in SmartBrief does not necessarily reflect the official position of SNM.
Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent SNM SmartBrief Issues:   Lead Editor:  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information